Objective: To evaluate the efficacy and safety of Tibetan medicine Ruyi Zhenbao Pills(RZPs) in the treatment of patients with motor and sensory dysfunction after stroke. Methods: A total of 120 convalescent stroke pat...Objective: To evaluate the efficacy and safety of Tibetan medicine Ruyi Zhenbao Pills(RZPs) in the treatment of patients with motor and sensory dysfunction after stroke. Methods: A total of 120 convalescent stroke patients hospitalized in the Rehabilitation Department of Guangdong Provincial Hospital of Chinese Medicine from June 2017 to December 2019 were enrolled in this trial. Patients were assigned to control(60 cases) and research(60 cases) groups by computer random assignment. All patients received internal treatment and modern rehabilitation training. On this basis, the research group was given oral RZPs for 4 weeks, while the control group was given oral placebo. The primary outcome was motor function of the affected side evaluated by simplified FuglMeyer Motion Assessment Scale(FMA-M). The secondary outcomes included sensory function, activity of daily living(ADL), quality of life, balance function, and pain, which were assessed by Fugl-Meyer Sensory Assessment Scale(FMA-S), Modified Barthel Index(MBI), Special Scale of the Quality of Life(SS-QOL), Berg Balance Scale(BBS), and Visual Analogue Scale(VAS), respectively. All of the assessments were performed before treatment, and 4 and 8 weeks after treatment. Vital signs, liver and kidney functions, routine blood test, blood coagulation profile, and routine urinalysis of patients were monitored. Results: After 4-week treatment, the FMA-M, BBS and FMA-S scores in the research group significantly increased compared with the control group(P<0.05). At 8-week follow-up, the BBS and MBI scores in the research group were higher than the control group(P<0.05). There was no statistical difference between the 2 groups in the SS-QOL and VAS scores at 4 and 8 weeks(P>0.05). Moreover, after treatment, there was no significant difference in vital signs, liver and kidney functions, blood coagulation function, blood routine and urinalysis between the 2 groups(P>0.05). Conclusion: RZPs improved limb motor, balance, and sensory functions of stroke patients during recovery period with good safety.(Trial registration No. NCT04029701)展开更多
目的观察蒙药珍宝丸药物血清对体外培养雪旺细胞增殖的影响。方法选用新生24 h SD大鼠,取双侧坐骨神经,分离、培养并纯化雪旺细胞,用S-100免疫细胞化学染色法鉴定雪旺细胞,将纯化的雪旺细胞分别用胎牛血清、不同给药剂量大鼠血清、以及...目的观察蒙药珍宝丸药物血清对体外培养雪旺细胞增殖的影响。方法选用新生24 h SD大鼠,取双侧坐骨神经,分离、培养并纯化雪旺细胞,用S-100免疫细胞化学染色法鉴定雪旺细胞,将纯化的雪旺细胞分别用胎牛血清、不同给药剂量大鼠血清、以及不含药大鼠血清培养,并分别于培养的第1天、第4天以及第7天用MTT法观察各组雪旺细胞增殖情况。结果 (1)S-100免疫染色结果显示纯化后的雪旺细胞纯度为93.8%。(2)MTT法测得培养第7天时高剂量含药血清组OD值明显高于正常剂量含药血清组和不含药大鼠血清组OD值(P<0.05),而全过程中胎牛血清组OD值明显高于不含药大鼠血清组OD值(P<0.05)。结论蒙药珍宝丸药物血清在适度条件下可促进雪旺细胞的增殖。展开更多
基金Supported by SHEN Bao-fan Academic Experience Inheritance Studio of Guangdong Provincial Hospital of Chinese Medicine。
文摘Objective: To evaluate the efficacy and safety of Tibetan medicine Ruyi Zhenbao Pills(RZPs) in the treatment of patients with motor and sensory dysfunction after stroke. Methods: A total of 120 convalescent stroke patients hospitalized in the Rehabilitation Department of Guangdong Provincial Hospital of Chinese Medicine from June 2017 to December 2019 were enrolled in this trial. Patients were assigned to control(60 cases) and research(60 cases) groups by computer random assignment. All patients received internal treatment and modern rehabilitation training. On this basis, the research group was given oral RZPs for 4 weeks, while the control group was given oral placebo. The primary outcome was motor function of the affected side evaluated by simplified FuglMeyer Motion Assessment Scale(FMA-M). The secondary outcomes included sensory function, activity of daily living(ADL), quality of life, balance function, and pain, which were assessed by Fugl-Meyer Sensory Assessment Scale(FMA-S), Modified Barthel Index(MBI), Special Scale of the Quality of Life(SS-QOL), Berg Balance Scale(BBS), and Visual Analogue Scale(VAS), respectively. All of the assessments were performed before treatment, and 4 and 8 weeks after treatment. Vital signs, liver and kidney functions, routine blood test, blood coagulation profile, and routine urinalysis of patients were monitored. Results: After 4-week treatment, the FMA-M, BBS and FMA-S scores in the research group significantly increased compared with the control group(P<0.05). At 8-week follow-up, the BBS and MBI scores in the research group were higher than the control group(P<0.05). There was no statistical difference between the 2 groups in the SS-QOL and VAS scores at 4 and 8 weeks(P>0.05). Moreover, after treatment, there was no significant difference in vital signs, liver and kidney functions, blood coagulation function, blood routine and urinalysis between the 2 groups(P>0.05). Conclusion: RZPs improved limb motor, balance, and sensory functions of stroke patients during recovery period with good safety.(Trial registration No. NCT04029701)
文摘目的观察蒙药珍宝丸药物血清对体外培养雪旺细胞增殖的影响。方法选用新生24 h SD大鼠,取双侧坐骨神经,分离、培养并纯化雪旺细胞,用S-100免疫细胞化学染色法鉴定雪旺细胞,将纯化的雪旺细胞分别用胎牛血清、不同给药剂量大鼠血清、以及不含药大鼠血清培养,并分别于培养的第1天、第4天以及第7天用MTT法观察各组雪旺细胞增殖情况。结果 (1)S-100免疫染色结果显示纯化后的雪旺细胞纯度为93.8%。(2)MTT法测得培养第7天时高剂量含药血清组OD值明显高于正常剂量含药血清组和不含药大鼠血清组OD值(P<0.05),而全过程中胎牛血清组OD值明显高于不含药大鼠血清组OD值(P<0.05)。结论蒙药珍宝丸药物血清在适度条件下可促进雪旺细胞的增殖。
